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Introduction
Cutaneous Polyarteritis Nodosa (cPAN) is a rare type of
vasculitis affecting small-to-medium-size arteries. It is dis-
tinct from systemic PAN in that it lacks significant internal
organ involvement. Familial Mediterranean Fever (FMF) is
the most common inherited autoinflammatory disease,
characterized by recurrent, self–limited attacks of fever
and aseptic polyserositis. PAN is considered one of the
four types of vasculitis associated with FMF. FMF is wide-
spread in Armenia and there is a higher than expected
frequency of FMF-associated vasculitis which may in some
cases be the first indication for MEFV mutation analysis.
Objectives
We want to introduce the importance of MEFV gene
analysis in the patients with vasculitis in population
with high prevalence of FMF.
Methods
A case report of a patient diagnosed and followed in
multidisciplinary unit.
Results
A 7 years old girl was admitted to the hospital with the
following complaints: high grade fever for 3 days, stomati-
tis, ulcers on the feet, swelling and tenderness of the left
ankle joint. Past history was unremarkable. The physical
examination revealed livedo reticularis on the lower extre-
mities, painful subcutaneous nodules and ulcers on the left
leg and foot, arthritis of the left ankle joint. Blood pressure
was normal. No signs of internal organ involvement were
found. Initial laboratory findings indicated: mild anemia,
(Hbg-100g/l), thrombocytosis -700.000/mcl. elevated acute
phase reactants - leukocytes -26,000/mcl, with 81% of neu-
trophils, ESR 70 mm/h, and CRP 96 mg/l. An extensive
diagnostic work up including blood culture and serology
(ANA, anti dsDNA. ANCA, ACA, HBs Ag …),
biochemical examination, bone marrow aspirates and
imaging studies did not reveal any pathology. Despite of
absence of FMF symptoms, genetic analysis of MEFV
mutations was done and 2 mutations in compound
heterozygous (F148Q/P369S) state were found. Along with
prednisone, azathioprine, treatment with colchicine was
started. Later AZA was discontinued because of intoler-
ance. Prednisone was tapered and stopped within
6 months. Currently the patient is only on colchicine
treatment and in complete remission for both diseases.
Conclusion
In populations with a high prevalence of FMF, screening
of MEFV mutation is recommended for patients with
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